Michael Ehlers
Neuroscience Chief Scientific Officer
Pfizer
From this contributor
A cautionary tale for autism drug development
Poorly designed animal drug studies for motor disorders have led to spurious conclusions for the clinical trials that follow. This may be even more true for autism research, says Michael Ehlers.
SHANK mutations converge at neuronal junctions in autism
SHANK3, one of the strongest candidate genes for autism, has the potential to be a molecular entry point into understanding the synaptic, developmental and circuit origins of the disorder.
SHANK mutations converge at neuronal junctions in autism
Drug zone
Rodent and stem cell models remain challenging for developing psychiatric drugs, says Michael Ehlers, chief scientific officer of neuroscience at Pfizer.
Explore more from The Transmitter
Neuroscientists reeling from past cuts advocate for more BRAIN Initiative funding
The director of the U.S. National Institutes of Health calls BRAIN a “high priority” but acknowledges that difficult decisions lie ahead if federal budgets remain flat.
Neuroscientists reeling from past cuts advocate for more BRAIN Initiative funding
The director of the U.S. National Institutes of Health calls BRAIN a “high priority” but acknowledges that difficult decisions lie ahead if federal budgets remain flat.
‘Huge influx’ of neuroscientists migrates to Bluesky
Daily neuroscience-related posts on the social-media platform this week have increased more than 400 percent, on average, compared with October.
‘Huge influx’ of neuroscientists migrates to Bluesky
Daily neuroscience-related posts on the social-media platform this week have increased more than 400 percent, on average, compared with October.
Autism prevalence increasing in children, adults, according to electronic medical records
The uptick from 2011 to 2022 in the United States underscores a need for more services and research, the investigators say.
Autism prevalence increasing in children, adults, according to electronic medical records
The uptick from 2011 to 2022 in the United States underscores a need for more services and research, the investigators say.